These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 37196530)

  • 1. Ticagrelor as Compared to Clopidogrel Following Percutaneous Coronary Intervention for Acute Coronary Syndrome.
    Wiens EJ; Leon SJ; Whitlock R; Tangri N; Shah AH
    Am J Cardiol; 2023 Jul; 198():26-32. PubMed ID: 37196530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different P2Y
    Choe JC; Cha KS; Ahn J; Park JS; Lee HW; Oh JH; Choi JH; Lee HC; Hong TJ; Jeong MH;
    Int J Cardiol; 2019 Jan; 274():21-26. PubMed ID: 30224257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.
    Hou M; Hyun K; Chew DP; Kritharides L; Amos D; Brieger D
    Heart Lung Circ; 2022 Aug; 31(8):1085-1092. PubMed ID: 35589483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US.
    Wang Y; Cavallari LH; Brown JD; Thomas CD; Winterstein AG
    JAMA Netw Open; 2023 Apr; 6(4):e238585. PubMed ID: 37067798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes.
    Koshy AN; Giustino G; Sartori S; Hooda A; Feng Y; Snyder C; Dasgupta S; Kumar KR; Krishnamoorthy-Melarcode P; Sweeny J; Khera S; Serrao GW; Sharma R; Dangas G; Kini AS; Mehran R; Sharma SK
    EuroIntervention; 2023 Mar; 18(15):1244-1253. PubMed ID: 36660810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes.
    Sachdeva A; Mutyala R; Mantri N; Zhu S; McNulty E; Solomon M
    J Interv Cardiol; 2023; 2023():1147352. PubMed ID: 37251366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
    Galli M; Benenati S; Franchi F; Rollini F; Capodanno D; Biondi-Zoccai G; Vescovo GM; Cavallari LH; Bikdeli B; Ten Berg J; Mehran R; Gibson CM; Crea F; Pereira NL; Sibbing D; Angiolillo DJ
    Eur Heart J; 2022 Mar; 43(10):959-967. PubMed ID: 34918066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Turgeon RD; Koshman SL; Youngson E; Har B; Wilton SB; James MT; Graham MM
    JAMA Intern Med; 2020 Mar; 180(3):420-428. PubMed ID: 31930361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry.
    Alexopoulos D; Xanthopoulou I; Deftereos S; Hamilos M; Sitafidis G; Kanakakis I; Pentara I; Vavouranakis M; Davlouros P; Hahalis G; Goudevenos J
    J Thromb Haemost; 2016 Jun; 14(6):1146-54. PubMed ID: 26990959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention.
    Kumar A; Lutsey PL; St Peter WL; Schommer JC; Van't Hof JR; Rajpurohit A; Farley JF
    Clin Pharmacol Ther; 2023 Feb; 113(2):412-422. PubMed ID: 36448257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet drug selection in PCI to vein grafts in patients with acute coronary syndrome and adverse clinical outcomes: Insights from the British Cardiovascular Intervention Society database.
    Sirker A; Kwok CS; Kontopantelis E; Johnson T; Freeman P; de Belder MA; Ludman P; Zaman A; Mamas MA
    Catheter Cardiovasc Interv; 2018 Oct; 92(4):659-665. PubMed ID: 29356278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.
    Wang Z; Zhou DY; Su Y; Si LY; Xu Q
    BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Ticagrelor and Clopidogrel in Patients With Acute Coronary Syndrome at High Bleeding or Ischemic Risk.
    Akyuz S; Calik AN; Yaylak B; Onuk T; Eren S; Kolak Z; Mollaalioglu F; Durak F; Cetin M; Tanboga IH
    Am J Cardiol; 2024 Jan; 210():241-248. PubMed ID: 37875237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within an Integrated Delivery System.
    Coons JC; Iasella CJ; Chanas T; Wang N; Williams K; Boyd A; Lyons J; Eckardt J; Rihtarchik L; Merkel A; Chambers A; Lemon LS; Smith R; Ensor CR
    Ann Pharmacother; 2017 Aug; 51(8):649-655. PubMed ID: 28438043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P2Y12 Inhibitors for Non-ST-Segment Elevation Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis.
    Fujisaki T; Kuno T; Briasoulis A; Misumida N; Takagi H; Latib A
    Tex Heart Inst J; 2023 May; 50(3):. PubMed ID: 37302149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials.
    Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Baral N; Adhikari G; Khan H; Hassan M
    Am J Cardiovasc Drugs; 2022 May; 22(3):287-298. PubMed ID: 34651261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prasugrel in the treatment of acute coronary syndrome.
    Spartalis M; Tzatzaki E; Spartalis E; Paschou SA; Athanasiou A; Iliopoulos DC; Siasos G; Voudris V
    Future Cardiol; 2020 Nov; 16(6):559-568. PubMed ID: 32390477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Effectiveness of Contemporary P2Y
    Yun JE; Kim YJ; Park JJ; Kim S; Park K; Cho MS; Nam GB; Park DW
    J Am Heart Assoc; 2019 Jul; 8(14):e012078. PubMed ID: 31310570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.
    Abraham NS; Yang EH; Noseworthy PA; Inselman J; Yao X; Herrin J; Sangaralingham LR; Ngufor C; Shah ND
    Aliment Pharmacol Ther; 2020 Aug; 52(4):646-654. PubMed ID: 32657466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-Analysis Comparing P2Y
    Baldetti L; Melillo F; Moroni F; Gallone G; Pagnesi M; Venuti A; Beneduce A; Calvo F; Gramegna M; Godino C; D'Ascenzo F; De Ferrari GM; Capodanno D; Cappelletti AM
    Am J Cardiol; 2020 Jun; 125(12):1815-1822. PubMed ID: 32305225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.